Novo Nordisk to open $130 million diabetes labs
November 3, 2014Manufacturing and Production, Sales and Marketing Denmark, Måløv, Novo Nordisk, Tresiba, Victoza, diabetes
Novo Nordisk has invested $130 million in new diabetes laboratories as the company looks to focus more strongly on the …
UK doctors are ignoring statin guidance
November 3, 2014Sales and Marketing British Medical Association, GPs, NHS, NICE, Royal College of GPs, Royal College of Physicians, statins
A survey of UK doctors has found that many are refusing to apply NICE advice to offer statin therapy to …
Reprieve for Boehringer plant as Chinese buyer comes forward
November 3, 2014Manufacturing and Production Boehringer, China, Petersburg, UniTao Pharmaceuticals
A US manufacturing facility cued up for closure by Boehringer Ingelheim has been bought by a Chinese drugmaker. Boehringer had …
Growing IPF drugs market evident at ERS Congress
November 3, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ERS, Esbriet, IPF, elf, european respiratory society, ofev
Arriving in Germany for this year’s European Respiratory Society (ERS) International Congress 2014, what awaited Pharmafile at the Ausgang was …
Takeda hires Merck senior head as president
November 3, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, marc princen
Marc Princen has joined Takeda Pharmaceuticals from Merck and is to serve as its corporate officer and president of the …
AbbVie financials beat expectations
October 31, 2014Sales and Marketing AbbVie, Abbott, Creon, Humira, Iopinavir/ritonavir, Kaletra, Q3, Synthroid, levothyroxine, pancrelipase
AbbVie has announced higher-than-expected financial results for the third quarter of 2014, although it continues to rely heavily on blockbuster …
BMS and Lonza announce expansion plans
October 31, 2014Manufacturing and Production, Sales and Marketing BMS, Lonza, Orencia, manufacturing, opdivo
Bristol-Myers Squibb (BMS) and Lonza are to expand upon an existing manufacturing agreement to meet anticipated demand for commercial biologics. …
NICE recommends new indication for troubled Pradaxa
October 31, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, dabigatran, ingelheim, warfarin
NICE has recommended Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa for treating and preventing potentially-fatal blood clots in the legs …
BMS lung cancer drug scores in Phase II
October 31, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, NSCLC, bristol myers-squibb, odivo
Bristol-Myers Squibb is still in the hunt to gain significant market share in the PD-1 therapeutic vaccine race after releasing …
More cancer patients surviving for longer
October 31, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, bladder, breast, myeloma, oncology, ons, prostate
Cancer survival rates in England are continuing to improve, though many cancers still have an ‘extremely poor’ prognosis, according to …
Carmago hires drug development head
October 31, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing carmago, steven castillo
US drug development firm Camargo Pharmaceutical Services has expanded its leadership team with the appointment of Steven Castillo as vice …
Microsoft enters into wearables market
October 30, 2014Medical Communications, Sales and Marketing Apple, Microsoft, band, fitness, health, watch, wearable, wearables
Microsoft has launched a new wearable heath tracking device as it looks to battle with Apple and Samsung in an …
Two neuroscientists join Biogen Idec
October 30, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen IDEC, richard ransohoff
Christopher Henderson and Richard Ransohoff have joined Biogen Idec to lead the company’s neurology research and discovery efforts. Henderson joins …
Takeda and Lilly get Actos trial reprieve
October 29, 2014Sales and Marketing Actos, Takeda, bladder cancer, diabetes, lilly
A judge has dramatically reduced the $9 billion damages bill Takeda and Lilly were set to pay over safety allegations …
Sovaldi misses estimates but still makes history
October 29, 2014Research and Development, Sales and Marketing FDA, Gilead, harvoni, hep C, sofosbuvir, sovaldi
The trajectory of Gilead’s new hep C pill Sovaldi has slowed but the drug is still on course to break …
Sanofi’s chief executive ousted
October 29, 2014Medical Communications, Research and Development, Sales and Marketing Christopher Viehbacher, Sanofi
Sanofi’s chief executive Chris Viehbacher has been ejected from his role after the French firm’s board lost patience with his …
Google X developing diagnosis pill
October 29, 2014Medical Communications, Research and Development, Sales and Marketing AbbVie, Pfizer, calico, diagnosis pill, google, google x, vida, wearables
Google is developing a new pill designed to send microscopic particles into the bloodstream in an effort to identify cancers, …
Cancer Drugs Fund ‘papering over the cracks of a bigger issue’
October 29, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, Kadcyla, NICE, breast cancer, reform
Breakthrough Breast Cancer has raised concerns to the government this week over the ever-increasing price of new oncology medicines. Over …
Quantum promotes senior head
October 29, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alison Doering, quantam pharmaceutical
Alison Doering has been promoted to head of group marketing and communications at medicines manufacturing firm Quantum Pharmaceutical. Doering will …
PrimeVigilance Limited upgrades its validated databases for pharmacovigilance and medical information – ARISg™ and agInquirer™.
October 28, 2014PrimeVigilance Limited, a pharmaceutical service provider for Pharmacovigilance and Medical Information operations today announced the completion of a major upgrade …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
